Anthera Pharmaceuticals to Present at the Citi Global Health Care Conference
HAYWARD, Calif., Feb. 23, 2012 /PRNewswire/ — Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that Paul F. Truex, Anthera’s President and Chief Executive Officer, will provide a corporate presentation at the Citi Global Health Care Conference in New York, NY on Monday, February 27, 2012, at approximately 2:00 pm Eastern Time.
Citi 2012 Global Health Care Conference Presentation
Date/Time: Monday, February 27, at 2:00 pm Eastern Time
Location: The Waldorf Astoria Hotel
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623). Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF) which have been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., email@example.com or 510.856.5586.
SOURCE Anthera Pharmaceuticals, Inc.